Do analysts rate IBIO or SNDL?

iBio currently has a consensus target price of $4.75, indicating a potential upside of 170.66%. SNDL has a consensus target price of $5.00, indicating a potential upside of 252.16%. Given SNDL's higher possible upside, analysts clearly believe SNDL is more favorable than iBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.17 SNDL 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, IBIO or SNDL?

SNDL has higher revenue and earnings than iBio. SNDL is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $400K 217.97 -$18.38M -$0.58 N/A SNDL $677.32M 0.54 -$11.29M -$0.03 N/A

Is IBIO or SNDL more profitable?

iBio has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% SNDL -1.19% -1.02% -0.85%

Does the media favor IBIO or SNDL?

In the previous week, SNDL had 5 more articles in the media than iBio. MarketBeat recorded 10 mentions for SNDL and 5 mentions for iBio. SNDL's average media sentiment score of 1.17 beat iBio's score of 0.35 indicating that SNDL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SNDL 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PBYI or IBIO?

iBio has a consensus price target of $4.75, indicating a potential upside of 170.66%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 iBio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.17

Which has stronger earnings & valuation, PBYI or IBIO?

Puma Biotechnology has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Puma Biotechnology $228.40M 1.56 $31.11M $0.48 14.56 iBio $400K 217.97 -$18.38M -$0.58 N/A

Is PBYI or IBIO more profitable?

Puma Biotechnology has a net margin of 10.69% compared to iBio's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Puma Biotechnology 10.69% 20.30% 12.05% iBio N/A -53.86% -46.48%

Is IBIO or LRMR more profitable?

iBio's return on equity of -53.86% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Larimar Therapeutics N/A -134.14% -96.00%

Does the media favor IBIO or LRMR?

In the previous week, iBio had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 5 mentions for iBio and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.54 beat iBio's score of 0.35 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, CLLS or IBIO?

iBio has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectis $79.59M 3.98 -$67.59M -$0.67 N/A iBio $400K 217.97 -$18.38M -$0.58 N/A

Is CLLS or IBIO more profitable?

iBio has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. iBio's return on equity of -53.86% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -89.51% -80.66% -20.51% iBio N/A -53.86% -46.48%

Do analysts prefer AVIR or IBIO?

iBio has a consensus target price of $4.75, suggesting a potential upside of 170.66%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 iBio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.17

Is AVIR or IBIO more profitable?

iBio's return on equity of -53.86% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% iBio N/A -53.86% -46.48%

Does the media prefer AVIR or IBIO?

In the previous week, iBio had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 5 mentions for iBio and 3 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.04 beat iBio's score of 0.35 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iBio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

iBio (IBIO) Competitors

$1.75 -0.01 (-0.57%)

As of 12:21 PM Eastern

Compare

IBIO vs. SNDL, PBYI, LRMR, CLLS, and AVIR

Should you buy iBio stock or one of its competitors? MarketBeat compares iBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with iBio include SNDL (SNDL), Puma Biotechnology (PBYI), Larimar Therapeutics (LRMR), Cellectis (CLLS), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.

How does iBio compare to SNDL?

iBio (NASDAQ:IBIO) and SNDL (NASDAQ:SNDL) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, SNDL had 5 more articles in the media than iBio. MarketBeat recorded 10 mentions for SNDL and 5 mentions for iBio. SNDL's average media sentiment score of 1.17 beat iBio's score of 0.35 indicating that SNDL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SNDL	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
SNDL	-1.19%	-1.02%	-0.85%

SNDL has higher revenue and earnings than iBio. SNDL is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	217.97	-$18.38M	-$0.58	N/A
SNDL	$677.32M	0.54	-$11.29M	-$0.03	N/A

iBio currently has a consensus target price of $4.75, indicating a potential upside of 170.66%. SNDL has a consensus target price of $5.00, indicating a potential upside of 252.16%. Given SNDL's higher possible upside, analysts clearly believe SNDL is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

7.9% of iBio shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

iBio has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, SNDL has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Summary

iBio beats SNDL on 9 of the 17 factors compared between the two stocks.

How does iBio compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Puma Biotechnology has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.56	$31.11M	$0.48	14.56
iBio	$400K	217.97	-$18.38M	-$0.58	N/A

Puma Biotechnology has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, iBio has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

iBio has a consensus price target of $4.75, indicating a potential upside of 170.66%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17

In the previous week, iBio had 4 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for iBio and 1 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.94 beat iBio's score of 0.35 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Puma Biotechnology	Positive
iBio	Neutral

Puma Biotechnology has a net margin of 10.69% compared to iBio's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
iBio	N/A	-53.86%	-46.48%

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by company insiders. Comparatively, 2.8% of iBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Puma Biotechnology beats iBio on 10 of the 17 factors compared between the two stocks.

How does iBio compare to Larimar Therapeutics?

iBio (NASDAQ:IBIO) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

iBio has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

In the previous week, iBio had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 5 mentions for iBio and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.54 beat iBio's score of 0.35 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

7.9% of iBio shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

iBio's return on equity of -53.86% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Larimar Therapeutics	N/A	-134.14%	-96.00%

iBio presently has a consensus price target of $4.75, indicating a potential upside of 170.66%. Larimar Therapeutics has a consensus price target of $15.29, indicating a potential upside of 373.24%. Given Larimar Therapeutics' higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

iBio has higher revenue and earnings than Larimar Therapeutics. iBio is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	217.97	-$18.38M	-$0.58	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Summary

iBio beats Larimar Therapeutics on 8 of the 14 factors compared between the two stocks.

How does iBio compare to Cellectis?

Cellectis (NASDAQ:CLLS) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

iBio has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. iBio's return on equity of -53.86% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
iBio	N/A	-53.86%	-46.48%

Cellectis has a beta of 2.86, suggesting that its stock price is 186% more volatile than the broader market. Comparatively, iBio has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

63.9% of Cellectis shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 2.8% of iBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, iBio had 3 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for iBio and 2 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat iBio's score of 0.35 indicating that Cellectis is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectis	Positive
iBio	Neutral

Cellectis presently has a consensus price target of $7.00, suggesting a potential upside of 121.52%. iBio has a consensus price target of $4.75, suggesting a potential upside of 170.66%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17

iBio has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.98	-$67.59M	-$0.67	N/A
iBio	$400K	217.97	-$18.38M	-$0.58	N/A

Summary

iBio beats Cellectis on 10 of the 17 factors compared between the two stocks.

How does iBio compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Atea Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, iBio has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

iBio's return on equity of -53.86% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
iBio	N/A	-53.86%	-46.48%

iBio has higher revenue and earnings than Atea Pharmaceuticals. iBio is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
iBio	$400K	217.97	-$18.38M	-$0.58	N/A

iBio has a consensus target price of $4.75, suggesting a potential upside of 170.66%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, iBio had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 5 mentions for iBio and 3 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.04 beat iBio's score of 0.35 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iBio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

iBio beats Atea Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBIO vs. The Competition

Export

Metric	iBio	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$87.19M	$941.72M	$4.29B	$12.44B
Dividend Yield	N/A	4.84%	7.92%	5.30%
P/E Ratio	-3.03	1.49	21.83	24.23
Price / Sales	217.97	118.75	134.90	126.08
Price / Cash	N/A	20.06	56.86	57.88
Price / Book	1.95	8.07	33.47	6.73
Net Income	-$18.38M	-$4.04M	$109.80M	$336.97M
7 Day Performance	-6.65%	0.04%	0.12%	0.79%
1 Month Performance	10.38%	75.99%	4.34%	5.38%
1 Year Performance	N/A	108.78%	16.39%	34.55%

iBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBIO iBio	3.8973 of 5 stars	$1.76 -0.3%	$4.75 +170.7%	N/A	$87.19M	$400K	N/A	100	News Coverage Gap Up
SNDL SNDL	3.511 of 5 stars	$1.45 +0.7%	$5.00 +244.8%	+13.4%	$373.23M	$937.39M	N/A	2,751	News Coverage Positive News Gap Down
PBYI Puma Biotechnology	1.2552 of 5 stars	$7.31 +0.6%	N/A	+112.2%	$372.08M	$228.40M	15.23	200	Positive News
LRMR Larimar Therapeutics	2.6907 of 5 stars	$3.52 +1.4%	$15.29 +334.3%	+50.0%	$365.67M	N/A	N/A	30
CLLS Cellectis	3.1135 of 5 stars	$3.63 -1.1%	$6.75 +86.0%	+126.8%	$364.23M	$68.07M	N/A	290	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBIO) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iBio (IBIO) Competitors

IBIO vs. SNDL, PBYI, LRMR, CLLS, and AVIR

How does iBio compare to SNDL?

Summary

How does iBio compare to Puma Biotechnology?

Summary

How does iBio compare to Larimar Therapeutics?

Summary

How does iBio compare to Cellectis?

Summary

How does iBio compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iBio (IBIO) Competitors

IBIO vs. SNDL, PBYI, LRMR, CLLS, and AVIR

How does iBio compare to SNDL?

Does the media favor IBIO or SNDL?

Is IBIO or SNDL more profitable?

Which has stronger earnings and valuation, IBIO or SNDL?

Do analysts rate IBIO or SNDL?

Do insiders & institutionals hold more shares of IBIO or SNDL?

Which has more risk and volatility, IBIO or SNDL?

Summary

How does iBio compare to Puma Biotechnology?

Which has stronger earnings & valuation, PBYI or IBIO?

Which has more risk & volatility, PBYI or IBIO?

Do analysts prefer PBYI or IBIO?

Does the media prefer PBYI or IBIO?

Is PBYI or IBIO more profitable?

Do institutionals and insiders believe in PBYI or IBIO?

Summary

How does iBio compare to Larimar Therapeutics?

Which has more volatility & risk, IBIO or LRMR?

Does the media favor IBIO or LRMR?

Do insiders & institutionals believe in IBIO or LRMR?

Is IBIO or LRMR more profitable?

Do analysts recommend IBIO or LRMR?

Which has preferable valuation & earnings, IBIO or LRMR?

Summary

How does iBio compare to Cellectis?

Is CLLS or IBIO more profitable?

Which has more risk and volatility, CLLS or IBIO?

Do insiders and institutionals have more ownership in CLLS or IBIO?

Does the media prefer CLLS or IBIO?

Do analysts recommend CLLS or IBIO?

Which has better earnings and valuation, CLLS or IBIO?

Summary

How does iBio compare to Atea Pharmaceuticals?

Which has more risk and volatility, AVIR or IBIO?

Is AVIR or IBIO more profitable?

Which has preferable valuation & earnings, AVIR or IBIO?

Do analysts prefer AVIR or IBIO?

Do institutionals & insiders have more ownership in AVIR or IBIO?

Does the media prefer AVIR or IBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools